Johnson & Johnson (NYSE: JNJ) reported third-quarter results above Wall Street expectations on Tuesday and raised its full-year sales and adjusted earnings outlook, while setting a mid-2027 target for the planned separation of its DePuy Synthes orthopedics business.
Revenue for the quarter reached $25.4 billion, compared with analysts’ average estimate of $25.28 billion. Adjusted earnings were $2.59 per share, ahead of the $2.54 per-share estimate.
The company raised the midpoint of its full-year reported sales forecast to about $101.2 billion from $101.1 billion. It also increased the midpoint of its adjusted earnings outlook to $11.10 per share from $11.04.
Pharmaceutical revenue increased 7.7% to $16.76 billion during the quarter.
Darzalex, J&J’s blood cancer treatment, generated about $4.24 billion in sales, up roughly 16% from a year earlier. Analysts had expected $4.4 billion. Stelara sales declined 54% to $716 million as the drug faced generic competition. The figure remained above Wall Street expectations of $591 million.
Tremfya continued to offset some of the lost Stelara revenue following recent approvals in inflammatory bowel diseases. Sales of the immune disease treatment increased 68% to $2.4 billion, exceeding analyst estimates of approximately $2.19 billion.
Performance was softer in the company’s MedTech division. Sales rose 2.5% to $8.6 billion, below the $8.71 billion expected by analysts, according to LSEG data. Revenue outside the U.S. was essentially flat.
J.P. Morgan analyst Chris Schott said the MedTech shortfall was driven by the cardio and surgery businesses.
Chief Financial Officer Joe Wolk told Reuters that international results continued to face pressure from the Middle East conflict, austerity measures in Europe and pricing conditions in China. He said the conflict has not yet increased J&J’s costs, but has affected regional sales as some governments redirect spending toward defense.
Sales at the company’s Abiomed heart pump business also remained slow after a U.K. study earlier this year raised questions about the use of Impella pumps in certain high-risk coronary procedures.
J&J is also proceeding with plans to separate DePuy Synthes into an independent company. The company announced the planned orthopedics spinoff late last year as it continued shifting its portfolio toward other healthcare businesses. Wolk told outlets that J&J is targeting the middle of 2027 for the separation. He said the company has sufficient financial flexibility and does not need to pursue a transaction it considers less favorable.
Bloomberg News reported in September that Apollo Global Management was in talks to acquire the orthopedics business in a transaction that could value it at close to $20 billion.
J&J shares fell 5.5% in trading Tuesday.
About Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) was founded in 1886 and is headquartered in New Brunswick, New Jersey. The healthcare company operates through its Innovative Medicine and MedTech businesses.
At the time of publishing, Stocks.News holds positions in Johnson & Johnson as mentioned in the article.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
